CANADIAN CONFERENCE ON LYMPHOPROLIFERATIVE DISORDERS
MARCH 18-20, 2016 – LAKE LOUISE, ALBERTA
Comment On Twitter: #360PlanningSolutions
This event is an Accredited Group Learning Activity eligible for up to 12.0 Section 1 credits as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. This program has been reviewed and approved by UBC Division of Continuing Professional Development. Each physician should claim only those credits he/she actually spent in the activity.
WORDS OF WELCOME
8th Annual Canadian Conference on Lymphoproliferative Disorders (CCOLD)
Fairmont Chateau Lake Louise, Lake Louise, Alberta – March 18-20, 2016
On behalf of the planning committee, I have the pleasure of inviting you to the 8th Annual Canadian Conference on Lymphoproliferative Disorders (CCOLD).
CCOLD provides a unique opportunity for attendees to interact with international experts in the field of hematologic malignancies. The scope of this meeting will highlight both recent research findings elucidating the pathophysiology of these diverse diseases, as well as changes in therapeutic advances that have had a large impact in the management of our patients. As in previous meetings the format will be didactic presentations as well as case based panel discussions. The focus of the 2016 conference is on Amyloid / Multiple Myeloma, Chronic Lymphocytic Leukemia and Lymphomas. We will discuss practice changing research for Hodgkins and new therapies for indolent NHL including Follicular Lymphoma and Waldenstrom’s Macroglobulinemia. As we move into more novel therapies their cost continue to escalate which is challenging to manage with our ever tightening budget. CCOLD 2016 has pharmacoeconomics session which will be informative. There will be opportunity for audience participation via keypad polling devices with the entire faculty featured during the panel discussions.
Internationally known researchers in Lymphoproliferative and Plasma Cell Disorders will provide keynote lectures and their perspectives on optimal management. Confirmed visiting faculty include :
Dr. Randy Gascoyne, Vancouver, British Columbia
Dr. Christian Steidl, Vancouver, British Columbia
Dr. Morie A. Gertz, Rochester, MN, USA
Dr. Kerry Savage, Vancouver, British Columbia
Dr. Martin Hutchings, Copenhagen, Denmark
Dr. Joseph M. Connors, Vancouver, British Columbia
Dr. Richard Furman, New York, New York
Dr. Christopher Peacock, Edmonton, Alberta
Dr. Stuart Peacock, Vancouver, British Columbia
Dr. Tony Fields, Edmonton, Alberta
We will continue to support the “Young Investigators Research Awards Program” which has been very successful in providing educational and research support to trainees interested in Lymphoproliferative Disorders. Posters outlining their research will be focused at a special reception Saturday afternoon.
The organizing committee for the Allied Health Care Session have organized an exciting afternoon highlighting various topics in management of patients with LPD.
This event has been planned and implemented in accordance as an Accredited Group Learning activity (Section 1) as defined by the Maintenance of certification program of the Royal College of Physicians and Surgeons of Canada. This program will be reviewed by the UBC Division of Continuing Professional Development and Knowledge Translation.
CCOLD will be held at Lake Louise which is one of the most scenic alpine destinations. This provides the ideal setting to participate in this premier educational event and to network with your colleagues.
Dr. Wendy Lam
On behalf of the Planning Committee
Planning Committee :
Dr. Laurie Sehn, Vancouver, BC
Dr. Wendy Lam, Vancouver, BC
Dr. Doug Stewart, Calgary, AB
Dr. James Johnston, Winnipeg, MB
Dr. Christine Chen, Toronto, ON
Dr. Michael Crump, Toronto, ON
Dr. Chaim Shustik, Montreal, QC
Dr. Stephen Couban, Halifax, NS
This meeting has been designed to meet the educational needs of hematologists, oncologists, general practitioners in oncology and other health care providers involved in the management of patients with lymphoproliferative and plasma cell disorders.